← Back to Search

Autologous Chondrocyte Implantation

CartiLife® for Osteoarthritis and Articular Cartilage Injury

Phase 2
Recruiting
Research Sponsored by Biosolution Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 (pre-operation), and up to 24 months (post-operation)
Awards & highlights

Study Summary

This trial is testing whether a treatment for knee cartilage defects is safe and effective.

Eligible Conditions
  • Articular Cartilage Injury
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 (pre-operation), and up to 24 months (post-operation)
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0 (pre-operation), and up to 24 months (post-operation) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Knee
Cartilage
Secondary outcome measures
Change in IKDC (International Knee Documentation Committee) Score
Knee
Knee
+10 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CartiLife®Experimental Treatment1 Intervention
Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.

Find a Location

Who is running the clinical trial?

Biosolution Co., Ltd.Lead Sponsor
4 Previous Clinical Trials
159 Total Patients Enrolled
Jungsun Lee, Ph.DStudy DirectorBiosolution Co., Ltd.
1 Previous Clinical Trials
104 Total Patients Enrolled

Media Library

Articular Cartilage Injury Research Study Groups: CartiLife®
~5 spots leftby Jun 2025